A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)



Status:Recruiting
Conditions:Chronic Obstructive Pulmonary Disease, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:40 - Any
Updated:3/29/2019
Start Date:March 29, 2018
End Date:June 25, 2019
Contact:US GSK Clinical Trials Call Center
Email:GSKClinicalSupportHD@gsk.com
Phone:877-379-3718

Use our guide to learn which trials are right for you!

A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease

COPD is a progressive disease characterized by increasing obstruction to airflow and the
progressive development of respiratory symptoms including chronic cough, increased sputum
production, dyspnea and wheezing. Once-daily triple therapy of an Inhaled Corticosteroid/
Long-acting Muscarinic Receptor Antagonists/ Long Acting Beta-Agonist (ICS/LAMA/LABA) that is
combination of FF/UMEC/VI in a single device is being developed with the aim of providing a
new treatment option for the management of advanced COPD. The primary purpose of this study
is to evaluate lung function and health related quality of life (HRQoL) after 84 days of
treatment with a single inhaler triple therapy combination of FF/ UMEC/VI once daily via the
ELLIPTA® dry powder inhaler (DPI) compared with tiotropium once daily via HANDIHALER®, in
subjects with COPD. Subjects will be randomized 1:1 to receive FF/UMEC/VI or tiotropium in
the morning for 84 days. Subjects will also receive albuterol/salbutamol as a rescue therapy
throughout the study. Approximately 848 subjects with advanced COPD will be enrolled in the
study. The total study duration will be approximately 17 weeks including, 4-week run-in
period, 12-week treatment period and a 1-week follow-up period. ELLIPTA is a registered
trademark of GlaxoSmithKline (GSK) group of companies. HANDIHALER and RESPIMAT are registered
trademarks of Boeringher Ingelheim.


Inclusion Criteria:

- Subjects capable of giving signed informed consent.

- Outpatients will be included in the study.

- Subjects 40 years of age or older at Screening (Visit 1).

- Male or female subjects will be included; a female subject is eligible to participate
if she is not pregnant, not breastfeeding, and at least one of the following
conditions applies: not a woman of childbearing potential (WOCBP) or a WOCBP who
agrees to follow the contraceptive guidance during the treatment period and until the
safety follow-up contact after the last dose of study treatment.

- An established clinical history of COPD in accordance with the definition by the
American Thoracic Society/European Respiratory Society.

- Current or former cigarette smokers with a history of cigarette smoking of >=10
pack-years at Screening (Visit 1) (number of pack years = [number of cigarettes per
day / 20] x number of years smoked [example given {e.g.}, 20 cigarettes per day for 10
years, or 10 cigarettes per day for 20 years]). Previous smokers are defined as those
who have stopped smoking for at least 6 months prior to Visit 1.

- A score of >=10 on the COPD Assessment Test (CAT) at Screening (Visit 1).

- Subjects must demonstrate at Screening: A post-bronchodilator FEV1 <50 percent
predicted normal or a post-bronchodilator FEV1 <80 percent predicted normal and a
documented history of >=2 moderate exacerbations or one severe (hospitalized)
exacerbation in the previous 12 months. Subjects must also have a measured post
albuterol/salbutamol FEV1/forced vital capacity (FVC) ratio of <0.70 at screening.

- Subjects must have been receiving daily maintenance treatment with tiotropium alone
(via the HANDIHALER or RESPIMAT®) for their COPD for at least 3 months prior to
Screening.

Exclusion Criteria:

- Women who are pregnant or lactating or are planning on becoming pregnant during the
study.

- Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma
are eligible if they have a current diagnosis of COPD).

- Subjects with alpha1-antitrypsin deficiency as the underlying cause of COPD.

- Subjects with active tuberculosis, lung cancer, and clinically significant:
bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung
disease or other active pulmonary diseases.

- Subjects who have undergone lung volume reduction surgery within the 12 months prior
to Screening.

- Immune suppression (e.g. advanced human immunodeficiency virus [HIV] with high viral
load and low cluster of differentiation 4 [CD4] count, lupus on immunosuppressant's)
that in the opinion of the investigator would increase risk of pneumonia or other risk
factors for pneumonia (e.g. neurological disorders affecting control of the upper
airway, such as Parkinson's Disease, Myasthenia Gravis). Subjects at potentially high
risk for pneumonia (e.g. very low body mass index [BMI], severely malnourished, or
very low FEV1) will only be included at the discretion of the Investigator.

- Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least
14 days prior to Screening and at least 30 days following the last dose of
oral/systemic corticosteroids (if applicable).

- Respiratory tract infection that has not resolved at least 7 days prior to Screening.

- Chest x-ray (posteroanterior and lateral) reveals evidence of pneumonia or a
clinically significant abnormality not believed to be due to the presence of COPD, or
another condition that would hinder the ability to detect an infiltrate on chest x-ray
(e.g. significant cardiomegaly, pleural effusion or scarring). All subjects will have
a chest x-ray at Screening Visit 1 (or historical radiograph or computerized
tomography [CT] scan obtained within 3 months prior to screening). For sites in
Germany: If a chest x-ray (or CT scan) within 3 months prior to Screening (Visit 1) is
not available, approval to conduct a diagnostic chest x-ray will need to be obtained
from the Federal Office for Radiation Protection (BfS).

- Subjects with historical or current evidence of clinically significant cardiovascular,
neurological, psychiatric, renal, hepatic, immunological, gastrointestinal,
urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including
uncontrolled diabetes or thyroid disease) or hematological abnormalities that are
uncontrolled. Significant is defined as any disease that, in the opinion of the
Investigator, would put the safety of the subject at risk through participation, or
which would affect the efficacy or safety analysis if the disease/condition
exacerbated during the study.

- Alanine Transaminase (ALT) >2x Upper Limit of Normal (ULN); and bilirubin >1.5x ULN
(isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct
bilirubin <35 percent). Current active liver or biliary disease (with the exception of
Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver
disease per investigator assessment). Chronic stable hepatitis B and C (e.g., presence
of hepatitis B surface antigen [HBsAg] or positive hepatitis C antibody test result at
screening or within 3 months prior to first dose of study treatment) are acceptable if
subject otherwise meets entry criteria.

- Subjects with any of the following at Screening (Visit 1): myocardial infarction or
unstable angina in the last 6 months; unstable or life threatening cardiac arrhythmia
requiring intervention in the last 3 months; New York Heart Association (NYHA) Class
IV Heart failure.

- Abnormal and clinically significant 12-lead electrocardiogram (ECG) finding at Visit
1. The Investigator will determine the clinical significance of each abnormal ECG
finding in relation to the Subject's medical history and exclude subjects who would be
at undue risk by participating in the trial. An abnormal and clinically significant
finding that would preclude a subject from entering the trial is defined as a 12-lead
ECG tracing that is interpreted at, but not limited to, any of the following: atrial
fibrillation (AF) with rapid ventricular rate >120 beats per minute (BPM); sustained
and non-sustained ventricular tachycardia (VT); second degree heart block Mobitz type
II and third degree heart block (unless pacemaker or defibrillator had been inserted);
QT interval corrected for heart rate (QTc) >=500 millisecond (msec) in subjects with
QRS <120 msec and QTc >=530 msec in subjects with QRS >=120 msec.

- A history of allergy or hypersensitivity to any corticosteroid,
anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or
magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic
hypertrophy or bladder neck obstruction that, in the opinion of the Investigator,
contraindicates study participation.

- Subjects with carcinoma that has not been in complete remission for at least 3 years.
Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma and
basal cell carcinoma of the skin would not be excluded based on the 3 year waiting
period if the subject has been considered cured by treatment.

- Use of long-term oxygen therapy (LTOT) described as resting oxygen therapy >3 Liters
per minute (L/minute) (Oxygen use <=3 L/minute flow is not exclusionary.)

- Subjects who are medically unable to withhold their albuterol/salbutamol for the
4-hour period required prior to spirometry testing at each study visit.

- Subjects who have participated in the acute phase of a Pulmonary Rehabilitation
Programme within 4 weeks prior to screening or subjects who plan to enter the acute
phase of a Pulmonary Rehabilitation Programme during the study. Subjects who are in
the maintenance phase of a Pulmonary Rehabilitation Programme are not excluded.

- Subjects with a known or suspected history of alcohol or drug abuse within the last 2
years.

- Subjects at risk of non-compliance, or unable to comply with the study procedures. Any
infirmity, disability, or geographic location that would limit compliance for
scheduled visits.

- Subjects with a history of psychiatric disease, intellectual deficiency, poor
motivation or other conditions that will limit the validity of informed consent to
participate in the study.

- Study Investigators, sub-Investigators, study coordinators, employees of a
participating Investigator or study site, or immediate family members of the
aforementioned that is involved with this study.

- In the opinion of the Investigator, any subject who is unable to read and/or would not
be able to complete study related materials.

- Subjects taking following drug therapies will be excluded; subjects taking inhaled
short-acting anticholinergics alone or along with short-acting beta agonist
combination within 6 hours prior to screening; subjects taking inhaled short-acting
beta2 agonists within >=4 hours prior to screening; subjects taking ICS, ICS/inhaled
LABA combinations (e.g., FF/salmeterol, mometasone furoate/formoterol fumarate,
budesonide/formoterol fumarate; FF/VI), Phosphodiesterase 4 (PDE4) inhibitors
(roflumilast), LABA (e.g., indacaterol, olodaterol), LAMA (e.g., LAMA/LABA
combinations UMEC, aclidinium, glycopyrronium), LAMA/LABA combinations, theophyllines,
sodium cromoglycate and nedocromil sodium, anti-leukotrienes as maintenance treatment
within 3 months prior to Visit 1 will be excluded. Maintenance treatment is defined as
use for >=14 consecutive days (at any time in the 3 months prior to Visit 1). Subjects
taking long term antibiotic therapy. (Antibiotics are allowed for the short term
treatment (<=14 days) of an exacerbation or for short term treatment (<=14 days) of
other acute infections during the study); subjects taking systemic, oral, parenteral
corticosteroids 30 days prior to screening; (During the study oral/systemic
corticosteroids may be used for <=14 days to treat COPD exacerbations/pneumonia) will
be excluded. Intra-articular injections are allowed; subjects taking any other
investigational drug within 30 days or 5 half-lives whichever is longer prior to
screening will be excluded.
We found this trial at
33
sites
Seneca, South Carolina 29678
Principal Investigator: Ravi Chandran
Phone: 877-379-3718
?
mi
from
Seneca, SC
Click here to add this to my saved trials
Andalusia, Alabama 36420
Principal Investigator: Robert Garver
Phone: 877-379-3718
?
mi
from
Andalusia, AL
Click here to add this to my saved trials
Anderson, South Carolina 29621
Principal Investigator: Gowdhami Mohan
Phone: 877-379-3718
?
mi
from
Anderson, SC
Click here to add this to my saved trials
Bialystok, 15430
Principal Investigator: Beata Kuklinska
Phone: 877-379-3718
?
mi
from
Bialystok,
Click here to add this to my saved trials
Bronxville, New York 10708
Principal Investigator: Brooke J Nevins
Phone: 877-379-3718
?
mi
from
Bronxville, NY
Click here to add this to my saved trials
Cincinnati, Ohio 45229
Principal Investigator: Gregory M Gottschlich
Phone: 877-379-3718
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Colorado Springs, Colorado 80910
Phone: 877-379-3718
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Corsicana, Texas 75110
Principal Investigator: John D Updegrove
Phone: 877-379-3718
?
mi
from
Corsicana, TX
Click here to add this to my saved trials
Daytona Beach, Florida 32117
Principal Investigator: Dany Obeid
Phone: 877-379-3718
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Dublin, Ohio 43016
Principal Investigator: Sridhar Guduri
Phone: 877-379-3718
?
mi
from
Dublin, OH
Click here to add this to my saved trials
DuBois, Pennsylvania 15801
Principal Investigator: Sandeep Bansal
Phone: 877-379-3718
?
mi
from
DuBois, PA
Click here to add this to my saved trials
Edina, Minnesota 55435
Principal Investigator: Kevin Grullon
Phone: 877-379-3718
?
mi
from
Edina, MN
Click here to add this to my saved trials
Fayetteville, New York 13066
Principal Investigator: Sherif G El Bayadi
Phone: 877-379-3718
?
mi
from
Fayetteville, NY
Click here to add this to my saved trials
Gaffney, South Carolina 29340
Principal Investigator: David R Erb
Phone: 877-379-3718
?
mi
from
Gaffney, SC
Click here to add this to my saved trials
Gastonia, North Carolina 28054
Principal Investigator: Anup Banerjee
Phone: 877-379-3718
?
mi
from
Gastonia, NC
Click here to add this to my saved trials
Greer, South Carolina 29651
Principal Investigator: Ronald G DeGarmo
Phone: 877-379-3718
?
mi
from
Greer, SC
Click here to add this to my saved trials
Huntington Beach, California 92647
Principal Investigator: Bassil Aish
Phone: 877-379-3718
?
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Huntsville, Texas 77340
Principal Investigator: Sudhir Sehgal
Phone: 877-379-3718
?
mi
from
Huntsville, TX
Click here to add this to my saved trials
Kissimmee, Florida 34741
Principal Investigator: Thomas O'Brien
Phone: 877-379-3718
?
mi
from
Kissimmee, FL
Click here to add this to my saved trials
Little River, South Carolina 02956
Principal Investigator: Tom A Christensen
Phone: 877-379-3718
?
mi
from
Little River, SC
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Yamil Canaan
Phone: 877-379-3718
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami Lakes, Florida 33014
Principal Investigator: Idalia Acosta
Phone: 877-379-3718
?
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
Principal Investigator: Mitchell G Kaye
Phone: 877-379-3718
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Nampa, Idaho 83686
Principal Investigator: J'Cinda Bitters
Phone: 877-379-3718
?
mi
from
Nampa, ID
Click here to add this to my saved trials
Orlando, Florida 32806
Principal Investigator: Humberto Cruz
Phone: 877-379-3718
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Ormond Beach, Florida 32174
Principal Investigator: James R. Shoemaker
Phone: 877-379-3718
?
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Oxon Hill, Maryland 20745
Principal Investigator: Stephen T Ong
Phone: 877-379-3718
?
mi
from
Oxon Hill, MD
Click here to add this to my saved trials
Panama City, Florida 32405
Principal Investigator: Timothy G. Moriarty
Phone: 877-379-3718
?
mi
from
Panama City, FL
Click here to add this to my saved trials
Pelzer, South Carolina 29669
Principal Investigator: Daniel A Koontz
Phone: 877-379-3718
?
mi
from
Pelzer, SC
Click here to add this to my saved trials
Sacramento, California 95815
Principal Investigator: Jeffrey Wayne
Phone: 877-379-3718
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Salt Lake City, Utah 84132
Principal Investigator: Nirmal T Sunkara
Phone: 877-379-3718
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Simi Valley, California 93065
Phone: 877-379-3718
?
mi
from
Simi Valley, CA
Click here to add this to my saved trials
Spartanburg, South Carolina 29303
Principal Investigator: Farhan Siddiqui
Phone: 877-379-3718
?
mi
from
Spartanburg, SC
Click here to add this to my saved trials